Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V. Kotsakis A, et al. Among authors: katsaounis p. Lung Cancer. 2015 Apr;88(1):57-62. doi: 10.1016/j.lungcan.2015.01.012. Epub 2015 Jan 23. Lung Cancer. 2015. PMID: 25662596 Clinical Trial.
Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V. Katsaounis P, et al. Cancer Chemother Pharmacol. 2015 Apr;75(4):821-7. doi: 10.1007/s00280-015-2707-x. Epub 2015 Feb 22. Cancer Chemother Pharmacol. 2015. PMID: 25702051 Clinical Trial.
Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).
Matikas A, Kentepozidis Ν, Ardavanis A, Vaslamatzis M, Polyzos A, Emmanouilides Ch, Katsaounis P, Koinis F, Xynogalos S, Christopoulou A, Ziras N, Tegos T, Prinarakis E, Hatzidaki D, Georgoulias V, Kotsakis A; HORG’s Lung Cancer Working Group. Matikas A, et al. Among authors: katsaounis p. Cancer Chemother Pharmacol. 2016 Aug;78(2):369-76. doi: 10.1007/s00280-016-3094-7. Epub 2016 Jun 22. Cancer Chemother Pharmacol. 2016. PMID: 27335027 Clinical Trial.
Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A. Kentepozidis N, et al. Among authors: katsaounis p. Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4. Clin Transl Oncol. 2017. PMID: 27492015 Clinical Trial.
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece. Mavroudis D, et al. Among authors: katsaounis p. Ann Oncol. 2016 Oct;27(10):1873-8. doi: 10.1093/annonc/mdw274. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502729 Free article. Clinical Trial.
A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, Mavroudis D, Georgoulias V. Kotsakis A, et al. Among authors: katsaounis p. Br J Cancer. 2016 Sep 27;115(7):784-8. doi: 10.1038/bjc.2016.281. Epub 2016 Sep 8. Br J Cancer. 2016. PMID: 27607471 Free PMC article. Clinical Trial.
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A. Koinis F, et al. Among authors: katsaounis p. Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16. Br J Cancer. 2017. PMID: 28510571 Free PMC article. Clinical Trial.
Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J. Katsaounis P, et al. Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27. Ann Gastroenterol. 2018. PMID: 29333068 Free PMC article.
Small cell carcinoma of the stomach: A report of two cases and a review of the literature.
Bakogeorgos M, Kalkanis D, Katsaounis P, Ramfidis V, Speliades C, Pierrakou E, Papadopoulos S, Pantazopoulos N, Georgoulias V, Kotsakis A, Kentepozidis N. Bakogeorgos M, et al. Among authors: katsaounis p. Mol Clin Oncol. 2018 Jul;9(1):11-16. doi: 10.3892/mco.2018.1624. Epub 2018 May 10. Mol Clin Oncol. 2018. PMID: 29896397 Free PMC article.
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.
Matikas A, Souglakos J, Katsaounis P, Kotsakis A, Kouroupakis P, Pantazopoulos N, Kentepozidis N, Nikolaidi A, Messaritakis I, Tzovara I, Hatzidaki D, Prinarakis E, Georgoulias V. Matikas A, et al. Among authors: katsaounis p. Target Oncol. 2019 Jun;14(3):285-293. doi: 10.1007/s11523-019-00647-3. Target Oncol. 2019. PMID: 31203498 Clinical Trial.
22 results